Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca’s John Rex joins UK biotech F2G

Takes up the role of chief medical officer at the UK company

F2G John RexJohn Rex has moved from AstraZeneca to F2G to become the Manchester, UK-based drug discovery firm's chief medical officer.

He was previously a senior vice president at AZ, where he served as head of infection within its global medicines development unit, and he has been a non-executive director at F2G since 2012.

Ian Nicholson, chief executive officer at F2G, said: “John's guidance and insight have been instrumental in shaping F2G's development and regulatory strategy. We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”  

In his new role Rex will be tasked with helping move F2G's first-in-class antifungal F901218 through phase II clinical trials.

John Rex said: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal forward through phase II and phase III. Just as with antibacterial resistance, antifungal resistance is a growing threat and F2G's discovery of an entirely novel class of IV/PO antifungal agent is a key part of the global response to this challenge.”

Prior to joining AstraZeneca in 2003, Rex was professor of medicine at the University of Texas Medical School and has previously served as the industry representative on the US FDA Anti-Infective Drug Advisory Committee.

5th December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics